Actively Recruiting
Phase II Study of Pencil Beam Proton Therapy for Treating Pelvic Recurrences in Adults with Previously Irradiated Rectal Cancer
Led by University of Aarhus · Updated on 2021-01-05
65
Participants Needed
1
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating dose-escalated pencil beam proton therapy as a re-irradiation treatment for pelvic recurrences in patients with rectal cancer who have previously received radiotherapy. This phase II, non-randomized observational study focuses on using this therapy either as part of neo-adjuvant treatment or as a definitive approach for tumors that cannot be surgically removed. The study includes two experimental treatment groups one receiving neo-adjuvant pencil beam proton therapy with a dose of 55 GyRBE over 44 fractions 1.25 Gy per fraction administered twice daily, and another receiving definitive pencil beam proton therapy with doses ranging from 57.5 to 65 GyRBE over 46 to 52 fractions 1.25 Gy per fraction, also given twice daily. These treatments aim to assess the potential for local control of cancer in previously treated pelvic areas. Participants will be closely monitored throughout the study period with assessments including surgical resection outcomes, local control of cancer at one year, recurrence, disease-free survival, overall survival, treatment toxicity, and patient-reported outcomes over multiple years. The study involves comprehensive imaging and clinical follow-up to evaluate the safety and effectiveness of the re-irradiation approach over extended timelines up to 10 years after treatment.
CONDITIONS
Brief Title
Pencil Beam Proton Therapy for Pelvic Recurrences in Rectal Cancer Patients Previously Treated With Radiotherapy
Research Team
C
Camilla Kronborg, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here